Ellington Management Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ellington Management Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,000	Closed	-$299K	–	232
2020 Q1	$299K	Buy	3,000 +900	+43%	+$116K	0.07%	328
2019 Q4	$313K	Buy	+2,100	New	+$286K	0.07%	296
2019 Q2	–	Sell	-4,200	Closed	-$600K	–	681
2019 Q1	$600K	Buy	+4,200	New	+$548K	0.11%	203
2018 Q1	–	Sell	-4,700	Closed	-$633K	–	925
2017 Q4	$633K	Buy	+4,700	New	+$652K	0.1%	163
2016 Q4	–	Sell	-3,600	Closed	-$437K	–	672
2016 Q3	$437K	Buy	+3,600	New	+$485K	0.12%	321
2016 Q1	–	Sell	-1,500	Closed	-$211K	–	598
2015 Q4	$211K	Sell	1,500 -951	-39%	-$132K	0.07%	439
2015 Q3	$326K	Buy	+2,451	New	+$422K	0.09%	378
2015 Q1	–	Sell	-1,700	Closed	-$278K	–	749
2014 Q4	$278K	Buy	+1,700	New	+$282K	0.09%	355
2014 Q2	–	Sell	-2,400	Closed	-$333K	–	564
2014 Q1	$333K	Buy	+2,400	New	+$361K	0.1%	325

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ellington Management Group's JAZZ Position: Q2 2020 in Review

Ellington Management Group sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2020, closing a stake of 3,000 shares — an estimated $299K sold.

Ellington Management Group first reported a position in JAZZ in Q1 2014 and held it in 9 quarters. The position peaked at $633K in Q4 2017. 384 funds tracked by Wall St. Rank hold JAZZ as of Q2 2020.

Ellington Management Group reported no remaining Jazz Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Ellington Management Group sold 3,000 Jazz Pharmaceuticals shares in Q2 2020, an estimated $299K.
Ellington Management Group first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 9 quarters.
Ellington Management Group's Jazz Pharmaceuticals position peaked at $633K in Q4 2017.
384 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.